Back to Screener

Financial Services

Tanke Biosciences Corporation(TNBI)

Live Price

Offline

$0.02

+0.00% today

1Y Change

+0.00%

Window

Jun 23, 2025 โ†’ Jun 17, 2026

Market Cap
โ€”
Revenue Growth
0.0%
EPS Growth
-129.8%
Dividend Yield
0.0%

Coverage: 248 bars ยท Jun 23, 2025 โ†’ Jun 17, 2026

Research Briefing

A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.

Decision context

Research Snapshot

Tanke Biosciences Corporation (TNBI) is a Financial Services stock with listed on OTC. The stock last traded around $0.02 and up 0.0% across the available one-year price window (Jun 23, 2025 โ†’ Jun 17, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of -129.8%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS -129.8%, free cash flow -6.0% with operating margin -3038.1% and ROIC 99.0%. Valuation already assumes a fairly strong business story at price/sales 100.2. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines TNBI price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Financial Services peers on this page.

Sector Context

How this name stacks up against nearby peers on first-pass metrics.

Revenue Growth

Below sector median

0.0% vs +3.4% peer median

Operating Margin

Below sector median

-3038.1% vs +4.7% peer median

What Changed This Quarter

Latest report context and the signals most likely to have changed the story.

Latest report is on the board

2023 was reported on Dec 31, 2023, but the surprise data is still limited.

The operating picture looks softer than before

Revenue is at 0.0% and EPS is at -129.8%, with operating margin around -3038.1%.

Benchmark Comparison

Normalized Performance vs SPY

Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.

1Y shared range

TNBI

โ€”

Normalized return

SPY

โ€”

S&P 500

Excess Return

โ€”

Relative to SPY

TNBI Max Drawdown

-66.67%

Trailing 1Y

SPY Max Drawdown

โ€”

Trailing 1Y

Benchmark comparison is loading or unavailable right now.

Calendar-Year Returns

Uses the longest available daily history for TNBI and SPY.

Calendar-year return history is still loading or unavailable.
Tanke Biosciences Corporation logo

Company Overview

Tanke Biosciences Corporation

Other OTC

Tanke Biosciences Corporation, through its subsidiaries, develops, produces, markets, and sells animal nutrition and feed additive products. It operates in four segments: Organic Trace Mineral Additives, Functional Regulation Additives, Herbal Medicinal Additives, and Other. The company offers organic trace mineral additives under the Qili brand name; feed acidifiers, which are used to prevent microbial degradation of raw materials or finished feeds under the Qilicid name; seasonings; flavor enhancers that are used as the agent in the production of blended feed under the Tankeball name; and herbal medicinal additives blended with feed products under the Extra-Health, Qilimix, and Recoccider names. It also produces and markets multiple trace mineral premix products for livestock and poultry under the Qilimix name. In addition, the company provides natural sweeteners and attractants for use with feed for pigs, piglets, fish, and other aquatic animals under the Tankeball name; and water soluble organic multi-vitamin electrolyte, which is fed to animals through dissolving it in drinking water for the animals to consume. It serves mid-to-large sized feed product factories, large scale feed producers, and farmers. The company sells its products primarily in the People's Republic of China, Southeast Asia, and Latin America. Tanke Biosciences Corporation was founded in 1989 and is headquartered in Guangzhou, the People's Republic of China.

Leadership
Vincent W. Renz Jr.
IPO Date
May 11, 2012
Employees
130
Street Address
East Tower of Hui Hao Building
Mailing
Las Vegas, 510627
Region
Las Vegas, CN
Reporting Currency
USD
Investor Line
86 20 3885 9025
Last Updated
May 5, 2026
CIK: 0001452011ISIN: US87583Y1073
Reports in USDSEC Registered

Key Fundamentals

Valuation, growth, profitability, and balance sheet signals.

Valuation

P/E
โ€”
EV/EBITDA
โ€”
Price/Sales
100.2
Price/Book
โ€”

Growth

Revenue
0.0%
EPS
-129.8%
Free Cash Flow
-6.0%

Profitability

Gross Margin
81.4%
Operating Margin
-3038.1%
Net Margin
-3254.6%
ROE
86.0%
ROIC
99.0%

Balance Sheet

Debt/Equity
โ€”
Current Ratio
0.02

Earnings Reports

๐Ÿ“… Last reportedDec 31, 2023
PeriodB/MEPSEPS ฮ”RevenueRev ฮ”
โ€”
Dec 31, 23
-0.00
Est โ€”
โ€”
โ€”
Est โ€”
โ€”

Latest News

No news articles available

Official Releases

Company announcements and filings-style updates.

Official
No official releases available

Next Step

Keep the research moving

After the overview, the strongest next step is usually chart context or a tighter compare set.